Lenvatinib Plus Camrelizumab vs. Lenvatinib Monotherapy as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Cohort Study

Li, Q; Cao, MR; Yuan, GS; Cheng, X; Zang, MY; Chen, M; Hu, XY; Huang, J; Li, R; Guo, YB; Ruan, J; Chen, JZ

Chen, JZ (通讯作者)，Southern Med Univ, State Key Lab Organ Failure Res, Guangdong Prov Key Lab Viral Hepatitis Res, Dept Infect Dis,Nanfang Hosp, Guangzhou, Peoples R China.;Ruan, J (通讯作者)，Zhejiang Univ, Affiliated Hosp 1, Dept Med Oncol, Coll Med, Hangzhou, Peoples R China.

FRONTIERS IN ONCOLOGY, 2022; 12 ():

Abstract

BackgroundCombining an antiangiogenic agent with an anti-PD-1 agent is a promising strategy for unresectable hepatocellular carcinoma (HCC). AimsTo ex......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索